First Subcutaneous Injectable Approved to Treat Generalized Myasthenia Gravis
The subcutaneous formulation of argenx’s Vyvgart has been approved by the U.S. Food and Drug Administration to treat generalized myasthenia gravis.
FDA Approves Roche’s Columvi to Treat Diffuse Large B-Cell Lymphoma in Adults
The U.S. Food and Drug Administration has approved Roche’s Columvi, an antibody-based therapy chemically known as glofitamab.
mRNA-Based Vaccine Plus Keytruda Reduces the Risk of Melanoma Spread
Adding an experimental mRNA-based vaccine developed by Moderna and Merck & Co to Keytruda reduced the risk that melanoma would spread by 65 percent over treatment with the immunotherapy drug alone, according to a midstage trial.
Drug Granted Fast Track Approval to Treat Refractory Lupus Nephritis
The US Food and Drug Administration has granted fast track designation for Kyverna Therapeutics’ KYV-101 to treat refractory lupus nephritis.
Study Finds Meningitis Vaccine Shows Promise
According to a new study, a meningitis vaccine tested in two African countries has shown promise in the fight against the disease, eliciting immune responses against five main strains. The Phase III randomized trials were conducted on 1,800 people in the West African nations of Mali and The Gambia. The under-trial NmCV-5 vaccine, developed by […]
New Approach May Better Treat SLE
Findings in a recent study suggest that targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus.
Blood-Based Biomarkers Can Detect Alzheimer’s 10 Years Before Disease Onset
A new study shows that a protein called glial fibrillary acidic protein is a possible biomarker for very early stages of Alzheimer’s.
Study Links Persistent Tumor Mutation with Therapeutic Response to Immunotherapy Schedule
Investigators have found that a subset of mutations within the overall tumor mutation burden are less likely to be edited out as cancer evolves.
CDC Adds COVID-19 Vaccine to Its Routine Immunization Schedule
The Centers for Disease Control and Prevention updated its schedule of recommended immunizations to include COVID-19 shots and boosters for children, adolescents and adults.
NIH Provides $5.3 Million Grant to Study Down Syndrome
The first clinical trial for Down syndrome regression disorder is being funded by a five-year $5.3 million grant.